Jointly provided by the American Academy of CME, Inc. and E&S MedEd Group, Inc.
Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals.
Many PWHA experience elevated bleed rates, suggesting that there may be additional steps clinicians need to take to minimize bleeding in this patient population. This educational video roundtable is designed to improve clinicians’ knowledge regarding prophylactic FVIII replacement therapy in preventing bleeding and bleed-related complications. This education will also help clinicians better recognize factors that can decrease adherence to FVIII replacement strategies. It will also help them explore the potential role in new EHL products in improving adherence and overall outcomes on PWHA in order that they will be better able to utilize and tailor EHL products for appropriate patients.
This educational initiative is targeted toward hematologists who treat and/or manage patients with hemophilia A. Other members of the hemophilia care team may also participate
After completing this activity, the participant should be better able to:
Describe the current use/underuse of prophylactic factor VIII (FVIII) replacement therapy in preventing bleeding and bleed-related complications in people with hemophilia A (PWHA)
Identify treatment factors that can decrease adherence to FVIII replacement strategies
Compare the pharmacokinetic profiles of new extended half-life (EHL) products to traditional replacement products
Develop a strategy for how to incorporate new EHL products as part of an individualized approach to hemophilia A prophylaxis
Conflict Of Interest Disclosure Policy
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:
Manuel Carcao, MD Associate Professor, Department of Pediatrics University of Toronto, Clinician-Investigator The Hospital for Sick Children, Division of Hematology/Oncology Toronto, Canada
Dr. Carcao states that he serves on Advisory Boards for marketing purposes for Bayer Pharmaceuticals, Bioverativ/Sanofi, CSL Behring, Novo Nordisk, Octapharma, Pfizer Inc., Roche and Shire. He also states he serves on Advisory Boards for scientific information for Bayer Pharmaceuticals, Bioverativ/Sanofi, CSL Behring, Grifols, LFB Group, Novo Nordisk, Octapharma, Pfizer Inc, Roche, and Shire. He serves as a consultant for marketing purposes for Bioverativ/Sanofi and Novo Nordisk, and has received grant/research support from Bayer Pharmaceuticals, Bioverativ/Sanofi, CSL Behring, Novo Nordisk Inc., Octapharma, Pfizer Inc., and Shire.
Stacy E. Croteau, MD Director, Hemophilia and Von Willebrand Disease Program Boston Children’s Hospital Boston, Massachusetts
Dr. Croteau states that she serves on Advisory Boards for scientific information for Catalyst Biosciences, CSL-Behring, Genentech, Shire, Sigilon, Novo Nordisk, and Tremeau Pharmaceuticals. She is a Consultant for clinical trial design for Novo Nordisk. Dr Croteau serves on the board of the American Thrombosis and Hemostasis Network and Hemophilia Alliance. She has received Grant/Research Support from Pfizer, Spark Therapeutics, ATHN/Hemophilia of Georgia, and Boehringer Ingelheim. She has received honoraria for educational presentations (non-CME) from National Hemophilia Foundation Inhibitor Summit, and Octapharma Symposium.
Mark T. Reding, MD Director, Center for Bleeding and Clotting Disorders University of Minnesota Minneapolis, Minnesota
Dr. Reding states that he serves on Advisory Boards for scientific information for Bayer Pharmaceuticals, Bioverativ Therapeutics, Novo Nordisk, and Shire. He is a Consultant for clinical trial design for Bayer Pharmaceuticals, and is on the Promotional Speaker’s Bureau for Bayer Pharmaceuticals, Bioverativ Therapeutics, Novo Nordisk, and Shire. Dr. Reding has received Grant/Research Support from Bayer Pharmaceuticals and BioMarin Pharmaceutical.
Reviewer and Planning Committee Disclosures
Independent Reviewer Brenda Riske, RN, MSN, MBA, MPA, states that she has no relevant financial relationships to disclose.
Planning Committee Guy Young, MD, discloses he serves on Advisory Boards for scientific information for CSL Behring, Genentech/Roche, Grifols, Kedrion Biopharma, Novo Nordisk, and Shire. He is on the Promotional Speaker Bureaus for Bioverativ Pharmaceutical and Genentech, and has received Grant/Research Support from Genentech.
Laurie Ermentrout states that she has no relevant financial relationships to disclose.
Lisa Kehs states that she has no relevant financial relationships to disclose.
Lillian McVey states that she has no relevant financial relationships to disclose.
John JD Juchniewicz, MCIS, states that he has no relevant financial relationships with any commercial interests.
Paul Miniter, MS, states that he has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and E&S MedEd Group American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The American Academy of CME, Inc., designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the American Academy of CME, Inc. or E&S MedEd Group. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines.
Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
There are no fees for participating in this activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.